Literature DB >> 3796213

Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man.

J Pernow, J M Lundberg, L Kaijser.   

Abstract

Vascular effects of neuropeptide Y (NPY) and noradrenaline (NA) were studied in six human volunteers. Systemic infusion of human NPY for 40 min (5 pmol X kg-1 X min-1) increased arterial plasma NPY-like immunoreactivity (NPY-LI) from 12 +/- 2 to 356 +/- 30 pM. This concentration caused no systemic cardiovascular effects. The disappearance curve for NPY-LI was biphasic; the slopes of the two phases corresponding to half lives of 4.1 +/- 0.4 and 20 +/- 2 min respectively. Close i.a. infusion of human NPY in the forearm caused a slowly developing and dose dependent decrease in forearm blood flow (FBF) and increase in venous tone with maximal values of 44 +/- 6 and 235 +/- 81% of control respectively at 5 nmol X min-1. The corresponding values for NA (5 nmol X min-1) were 21 +/- 9 and 489 +/- 78% of control. A threshold concentration for a decrease in FBF was obtained at a plasma NPY-LI of 3.7 +/- 0.6 nM. The decrease in FBF caused by NPY was maintained for a much longer period compared to that of NA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3796213     DOI: 10.1016/0024-3205(87)90251-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Neuropeptide Y (NPY) metabolism by endopeptidase-2 hinders characterization of NPY receptors in rat kidney.

Authors:  J S Price; A J Kenny; N S Huskisson; M J Brown
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

2.  An experimental study of the neurogenic and the immunological contribution to "tennis elbow" in rats.

Authors:  E Haker; E Theodorsson; T Lundeberg
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

3.  Actions of constrictor (NPY and endothelin) and dilator (substance P, CGRP and VIP) peptides on pig splenic and human skeletal muscle arteries: involvement of the endothelium.

Authors:  J Pernow
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

4.  Facilitating laser Doppler measurements of cutaneous adrenergic vasoconstriction: a comparison of methods.

Authors:  D M Lipnicki; P D Drummond
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

5.  The effects of age on human venous responsiveness to neuropeptide Y.

Authors:  M L Lambert; I D Callow; Q P Feng; J M Arnold
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

6.  Neuropeptide Y and reserpine-resistant vasoconstriction evoked by sympathetic nerve stimulation in the dog skeletal muscle.

Authors:  J Pernow; T Kahan; J M Lundberg
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

7.  Effects of neuropeptide Y and agonists selective for neuropeptide Y receptor sub-types on arterioles of the guinea-pig small intestine and the rat brain.

Authors:  J Xia; T O Neild; N Kotecha
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

8.  Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure.

Authors:  Q P Feng; T Hedner; B Andersson; J M Lundberg; F Waagstein
Journal:  Br Heart J       Date:  1994-03

Review 9.  Peptides in the mammalian cardiovascular system.

Authors:  J Wharton; S Gulbenkian
Journal:  Experientia       Date:  1987-07-15

10.  Effects of neuropeptides and capsaicin on the canine tracheal vasculature in vivo.

Authors:  R O Salonen; S E Webber; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.